This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bedford, P. Articles by Hill, B. T. Search for Related Content PubMed PubMed Citation Articles by Bedford, P. Articles by Hill, B. T.

Differential Repair of Platinum-DNA Adducts in Human Bladder and Testicular Tumor Continuous Cell Lines

Laboratory of Cellular Chemotherapy, Imperial Cancer Research Fund Laboratories, Lincoln's Inn Fields, London WC2A 3PX [P. B., S. A. S., B. T. H.], and Department of Histopathology, Institute of Urology, St. Paul's Hospital, 24, Endell Street, London WC2H 9AE [P. B., M. C. W., J. R. W. M., B. T. H.], United Kingdom, and TNO Medical Biological Laboratory, Lange Kleiweg 139, 2280 AA Rijswijk, The Netherlands [A. M. J. F-S.]

The formation and removal of four platinum-DNA adducts were immunochemically quantitated in cultured cells derived from a human bladder carcinoma cell line (RT112) and from two lines derived from germ cell tumors of the testis (833K and SUSA), following exposure in vitro to 16.7 µM (5 µg/ml) cisplatin. RT112 cells were least sensitive to the drug and were proficient in the repair of all four adducts, whereas SUSA cells, which were 5-fold more sensitive, were deficient in the repair of DNA-DNA intrastrand cross-links in the sequences pApG and pGpG. Despite expressing a similar sensitivity to SUSA cells, 833K cells were proficient in the repair of all four adducts, although less so than the RT112 bladder tumor cells. In addition, SUSA cells were unable to repair DNA-DNA interstrand cross-links whereas 50–85% of these lesions were removed in RT112 and 833K cells 24 h following drug exposure. It is possible that the inability of SuSa cells to repair platinated DNA may account for their hypersensitivity to cisplatin.

¹ To whom requests for reprints should be addressed, at the Imperial Cancer Research Fund Laboratories, Lincoln's Inn Fields, London WC2A, United Kingdom.

Received 7/16/87. Revised 11/17/87. Revised 2/18/88. Accepted 2/29/88.

This article has been cited by other articles:

				B. W. Cooper, G. J. Veal, T. Radivoyevitch, M. J. Tilby, H. J. Meyerson, H. M. Lazarus, O. N. Koc, R. J. Creger, G. Pearson, G. M. Nowell, et al. A Phase I and Pharmacodynamic Study of Fludarabine, Carboplatin, and Topotecan in Patients With Relapsed, Refractory, or High-Risk Acute Leukemia Clin. Cancer Res., October 15, 2004; 10(20): 6830 - 6839. [Abstract] [Full Text] [PDF]